| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10910785 | Lung Cancer | 2015 | 38 Pages |
Abstract
- We evaluated the combination of gefitinib and pemetrexed in EGFR-mutated NSCLC.
- The ORR and the median PFS were 84.6% and 18.0Â m, respectively.
- The combination showed a tendency to be more effective in tumors with Del19.
- The hematological and non-hematological toxicities were mild.
- This regimen showed a high ORR, long median PFS, and acceptable toxicity.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Naruo Yoshimura, Shinzoh Kudoh, Shigeki Mitsuoka, Naoki Yoshimoto, Takako Oka, Toshiyuki Nakai, Tomohiro Suzumira, Kuniomi Matusura, Yoshihiro Tochino, Kazuhisa Asai, Tatsuo Kimura, Tomoya Kawaguchi, Kazuto Hirata,